Chinese Lung Cancer Surgical Group
1 clinical trials · Sponsor
◉ Watch Chinese Lung Cancer Surgical Group
| Record | Firm | Date |
|---|---|---|
| Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations (NCT01410214) | Chinese Lung Cancer Surgical Group | 2011-05-01 |
Track Chinese Lung Cancer Surgical Group automatically
Every clearance here is in the API, with alerts when new ones post.